Tel: 01789 267520

Latest News: Research

Letter to NHS England Requesting Review of EAP Type 1 Interim Policy Criteria

24 August 2017 / Posted in: Research

Sent on 23rd August from clinicians and advocacy groups, this asks for the age limit and SMN2 copy number restrictions on potential access to be removed.

Read full story

RG7916 FIREFISH trial now enrolling patients (though not in UK)

16 August 2017 / Posted in: Research

Roche has begun to enrol SMA patients in the FIREFISH Phase II trial of their splice-modifying drug, RG7916 (also known as RO7034067).

Read full story

Age of children who will be able to access the EAP for SMA Type 1 going forwards

07 August 2017 / Posted in: Research

We have clarified that, from now on going forwards (until we hear from NICE), children will have to be diagnosed by 7 months of age to be eligible. If you have a child who has already been diagnosed with SMA Type 1 who is older than this and not already on the EAP, please read more.

Read full story

NHS England Announces Interim Policy on EAP for SMA Type 1

04 August 2017 / Posted in: Research

All hospital costs for administering nusinersen to patients with SMA Type 1 will be provided by NHS England.

Read full story

Brief Report from the All Party Parliamentary Group that focused on nusinersen

21 July 2017 / Posted in: Research

Held on 18th July, this covered the current provision of nusinersen for infants with SMA Type 1 through the Expanded Access Programme (EAP) and what progress there has been towards the possibility of wider access.

Read full story

Biogen announces how long they intend to keep open UK EAP for SMA Type 1

13 July 2017 / Posted in: Research

They state that this will be for ‘the remainder of the year in the UK’ and that they will ‘re-evaluate the progress of the reimbursement progress and the EAP towards the end of 2017’.

Read full story

PTC Therapeutics Provide Preliminary Clinical Data on RG7916

11 July 2017 / Posted in: Research

PTC Therapeutics presented an update on their splice-modifying drug, RG7916, at the 2017 Cure SMA Conference in Orlando, USA.

Read full story

Discussion about access to nusinersen

06 July 2017 / Posted in: Research

The All Party Parliamentary Group (APPG) for Muscular Dystrophy will discuss access to nusinersen on Tuesday 18th July in the Houses of Parliament. SMA Support UK and families will be there.

Read full story

Announcing the successful outcome of the 9th SMA Europe Research call

06 July 2017 / Posted in: Research

Based on the recommendations received by its Scientific Advisory Board, SMA Europe have awarded a total of €357,800 towards 3 cutting-edge SMA research projects.

Read full story

Update from NHS England’s June 6th meeting about the SMA Type 1 EAP

05 July 2017 / Posted in: Research

Lead clinicians and centre service managers were called together. SMA Support UK was also present. Due to the election ‘purdah’ and the NHSE communications approval process no one at the meeting has been able to discuss what went on until now with the release of the meeting notes.

Read full story